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The European regulation on plant protection products (1107/2009) (EC, 2009a), the revisions to the bio-
cides Directive (COM[2009]267) (EC, 2009b), and the regulation concerning chemicals (Regulation (EC)
No. 1907/2006 ‘REACH’) (EC.2006) only support the marketing and use of chemical products on the basis
that they do not induce endocrine disruption in humans or wildlife species. In the absence of agreed guid-
ance on how to identify and evaluate endocrine activity and disruption within these pieces of legislation a
European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) task forcewas formed to provide
scientiﬁc criteria that may be used within the context of these three legislative documents. The resulting
ECETOC technical report (ECETOC, 2009a) and the associated workshop (ECETOC, 2009b) presented a sci-
ence-based concept on how to identify endocrine activity and disrupting properties of chemicals for both
human health and the environment. The synthesis of the technical report and the workshop report was
published by the ECETOC task force (Bars et al., 2011a,b). Speciﬁc scientiﬁc criteria for the determination
of endocrine activity and disrupting properties that integrate information from both regulatory (eco)tox-
icity studies and mechanistic/screening studies were proposed. These criteria combined the nature of the
adverse effects detected in studies which give concern for endocrine toxicity with an understanding of the
mode of action of toxicity so that adverse effects can be explained scientiﬁcally. A key element in the data
evaluation is the consideration of all available information in a weight-of-evidence approach. However, to
be able to discriminate chemicals with endocrine properties of low concern from those of higher concern
(for regulatory purposes), the task force recognised that the concept needed further reﬁnement. Following
a discussion of the key factors at a secondworkshop of invited regulatory, academic and industry scientists
(ECETOC, 2011), the task force developed further guidance, which is presented in this paper. For human
health assessments these factors include the relevance to humans of the endocrine mechanism of toxicity,
the speciﬁcity of the endocrine effectswith respect to other potential toxic effects, the potency of the chem-
ical to induce endocrine toxicity and consideration of exposure levels. For ecotoxicological assessments the
key considerations include speciﬁcity and potency, but also extend to the consideration of population rel-
evance and negligible exposure. It is intended that these complement and reinforce the approach originally
described and previously published in this journal (Bars et al., 2011a,b).
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-NC-ND license.1. Introduction
Recent European legislation (Plant Protection Products Regula-
tion 1107/2009; proposed new Biocidal Products Regulation
COM[2009]267) (EC, 2009a,b): has created a hazard based approval
criterion that only supports the marketing and use of chemicals on
the basis that they do not induce endocrine disruption in humans
or wildlife species. Substances with endocrine properties are also
subject to authorisation under the European regulation on
the Registration, Evaluation, Authorisation and Restriction of
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consequences of identifying a substance as an endocrine disrupting
chemical are severe. However, the fundamental scientiﬁc
criteria, necessary to deﬁne endocrine disrupting properties, are
not described in any of these legislative texts or accompanying
guidance.
Consequently, in response to these legislative developments
and in absence of regulatory criteria, the European Centre for Eco-
toxicology and Toxicology of Chemicals (ECETOC) formed a task
force to develop a science-based proposal on how to identify and
assess chemicals with endocrine disrupting properties (ECETOC,
2009a1). ECETOC presented this proposal at a workshop of regula-
tory, academic and industry scientists (Barcelona; June 29–30,
2009) to evaluate the approach as a concept for identifying endo-
crine disrupting properties within a regulatory context (ECETOC,
2009b1). The proposed guidance was reﬁned following input from
the workshop, and was published by Bars et al. (2011a,b). The pro-
posed scientiﬁc criteria integrated, in a weight of evidence approach,
information from regulatory (eco)toxicity studies and mechanistic/
screening studies. These criteria combined evidence for adverse ef-
fects detected in apical whole-organism studies with an understand-
ing of the mode of action (MoA) of endocrine toxicity. Brieﬂy, the
ﬁrst part of the guidance consisted of ﬂow charts describing data
combinations of evidence (or absence thereof) that would lead to
the determination that a substance had endocrine disrupting proper-
ties or not (the reader is referred to Bars et al., 2011a,b for details). In
addition, since not all chemicals with endocrine disrupting proper-
ties are of equal hazard, an assessment of potency was also proposed
as a second step to discriminate chemicals of high concern from
those of lower concern (for regulatory purposes). However, the ECE-
TOC task force recognised that this second part of the assessment
needed further reﬁnement.
A considerable amount of work has also been undertaken by
individual EU member states and organisations, which has gener-
ated approaches for determining endocrine disrupting properties
that have signiﬁcantly progressed current thinking in this area
(ECETOC, 2009a; BfR, 2011). Recognising this, the ECETOC task
force hosted a second workshop (Florence; May 9–10, 2011), the
aim of which was to evaluate the emerging guidance produced
by regulatory authorities and organisations, to identify areas of
concordance and difference, to consolidate the common scientiﬁc
themes, and provide a platform for constructive debate on areas
of potential difference. The outcome of that workshop has been
published in a separate report (ECETOC, 2011). This paper presents
the revisions made to the ECETOC guidance including some contri-
butions from that workshop, and represents the view of the ECE-
TOC task force. The focus of this paper is to elaborate on key
aspects of the second part of the ECETOC guidance, and it therefore
complements the approach previously published in this journal
(Bars et al., 2011a,b).2. Reﬁnements to the ECETOC proposal to identify EDCs of
regulatory concern for human health
The criteria proposed by the ECETOC task force (ECETOC, 2009a;
Bars et al., 2011a,b) were based on two requisite elements shared
by the broadly accepted deﬁnitions for endocrine disrupting chem-
icals (e.g. Weybridge, 1996; EC, 1999; IPCS, 2002; Japanese Minis-
try of the Environment, 2005), i.e. that exogenous substances need
to cause adverse effects in intact organisms and that the adverse
effect is caused by an endocrine MoA. In the development of the
original guidance Bars et al. (2011) adopted the Weybridge deﬁni-
tion. However, since the IPCS Bars et al., 2011a deﬁnition is1 ECETOC reports are available for free download at http://ecetoc.org/publications.currently the most widely accepted deﬁnition and also takes pop-
ulations into account, the IPCS deﬁnition has now also been
adopted in this revision to the guidance.
The current primary toxicology test methods for detecting
endocrine toxicity in mammals are the standard regulatory OECD
studies (e.g. the rodent two-generation reproduction study (TG
416), the extended one-generation reproductive toxicity study
(TG 443), the rodent chronic toxicity and oncogenicity studies
(TG 451, TG 452, TG 453), and the recently enhanced 28 day toxic-
ity study (TG 407)). Evidence for the MoA is best provided by (but
not limited to) the recently validated in vitro and in vivo screening
studies included in the US EPA Tier 1 endocrine test battery or lev-
els 2–4 of the OECD conceptual framework for the testing and
assessment of endocrine disrupting chemicals.
The ﬁrst part of the ECETOC guidance considers ﬁve scenarios to
guide the evaluation of available mammalian data to determine
whether a substance has endocrine properties. Only one scenario
(Scenario C; Bars et al., 2011) describes the data combination that
would result in the conclusion that there is sufﬁcient evidence of
endocrine disruption. This data combination is met when adverse
effects on endocrine relevant endpoints in apical or supporting
non-apical in vivo studies are supported by mechanistic data from
in vitro or in vivo studies, (i.e. the sequence of the biochemical and
cellular events that underlies the adverse effect is described and
understood, then conclusive proof of endocrine disruption can be
considered as established). The other four scenarios (Scenarios A,
B, D and E) describe data combinations from available studies that
would result in the conclusion that there is no or insufﬁcient evi-
dence of endocrine disruption, and are discussed in Bars et al.
(2011).
The principles of the WHO/IPCS conceptual framework for eval-
uating MoA for cancer and non-cancer endpoints (Boobis et al.,
2006, 2008) should be applied for the weight-of-evidence evalua-
tion of the available data. Brieﬂy, the framework requires a
description of the key toxicological events critical to the postulated
MoA, followed by conﬁrmation of a dose–response relationship,
and a temporal association of the key events and the toxicological
response. The strength, consistency and speciﬁcity of the effects
then need to be determined, and the biological plausibility of the
MoA and effects are evaluated. The framework also suggests that
other MoAs should be considered as a part of the overall weight
of the evidence. If, after applying this framework to the evaluation
of the available data, it is established that there is sufﬁcient evi-
dence to determine a substance as an endocrine disrupter, it is then
necessary to discriminate chemicals of high regulatory concern
from those of lower regulatory concern. This is an important con-
sideration because not all substances, for which there is evidence
of endocrine disruption, represent the same hazard to humans.
Therefore, they should not all be of equal regulatory concern and
subject to the same severe regulatory consequences, such as haz-
ard-based exclusion under the pesticides legislation and authorisa-
tion under REACH. This can be illustrated with the example of
caffeine, for which relevant adverse effects were observed in
in vivo studies and are supported by in vitro mechanistic data. De-
creased numbers of copora lutea, implantations and foetuses for F1
females were observed following dosing with caffeine in an apical
rat reproduction study (Bradford et al., 1983). In supporting in vivo
studies effects such as decreased sperm motility and increase
sperm density were recorded in a mouse reproduction study
(Gulati et al., 1984) and an increased incidence of resorptions
was observed in rat developmental toxicity studies (Bertrand
et al., 1965, 1970; Palm et al., 1978). In addition, an increased inci-
dence of pituitary adenomas and mammary tumours were found in
a 12 month rat chronic study (Yamagami et al., 1983) and in a
43 week mouse study (Welsch et al., 1988), respectively. Whilst
no effects were found in an in vitro hER activation study, oestradiol
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(Tinwell et al., 2011). The available data for caffeine fulﬁl Scenario
C of the ECETOC framework, i.e. there is evidence from apical and
supporting in vivo studies of adverse effects on endpoints that
are relevant for the assessment of endocrine disruption, which is
supported by mechanistic information from an in vitro study which
provides a plausible MoA for the adverse effects observed in the
in vivo studies. If caffeine were a chemical subject to REACH or
the pesticide legislation, and in the absence of further consider-
ation of additional factors such as potency, this chemical would
face severe regulatory consequences due to its intrinsic endocrine
disrupting properties. This example demonstrates that consider-
ation of additional factors is required to discriminate chemicals
of low concern from those that merit regulatory concern, otherwise
many chemicals of low concern could potentially be subject to
authorisation under REACH or phased out under the pesticide
and biocide legislations. It is however relevant to note that even
in the absence of potency considerations, caffeine, as a chemical,
would fail any risk assessment approach (except for pharmaceuti-
cals). The margin of exposure (MoE) for caffeine is from 15 to 35
between the adverse effects (mammary gland development and
pituitary tumours) observed in cancer bioassays (50 mg/kg/day in
mice; 120 mg/kg/day in rat) and the mean daily intake for a
70 kg human (240 mg/day). This example demonstrates the highly
conservative approach that is taken for the regulation of pesticides
and general chemicals where a margin of exposure of at least 100 is
required between the No Observed Adverse Effect Level (NOAEL)
from the most appropriate animal toxicity study and any human
exposure.
A number of factors were proposed in the original ECETOC guid-
ance to discriminate chemicals of low concern from those of higher
concern and these are further developed and modiﬁed in this pa-
per. A summary overview of these factors for human health assess-
ment is provided in Fig. 1, and is described in more detail in the
sections below.
Once it has been established that there is sufﬁcient evidence for
an endocrine disrupter of potential concern, the evaluation should
proceed with an assessment of whether the endocrine MoA is rel-
evant to humans (Section 2.1). The default assumption is to assume
human relevance unless there is good scientiﬁc evidence to dem-
onstrate otherwise. The evaluation of human relevance is followed
by an assessment of speciﬁcity, which is required to determine
whether the adverse effects observed occur at dose levels lowerWeight of evidence for definin
Evaluate po
ED of high concern
Human relevance?
Is the ED effect the mos
MOE < 1000?
ED of regulatory concern
Yes N
Yes
Yes
Fig. 1. Summary overview of reﬁned ECETOC proposal to identifythan other forms of toxicity, e.g. neuro-, hepato-, or cardio-toxicity
(Section 2.2). If the endocrine effect is not the most sensitive effect
in the database, then the substance should not be considered of
high regulatory concern for endocrine disruption and the sub-
stance should undergo risk assessment based on the most sensitive
adverse effect. If the endocrine effect is the most sensitive effect,
then the assessment proceeds to an evaluation of potency to deﬁne
substances as being in one of two categories (Section 2.3). Category
2 (low concern) should undergo standard risk assessment. In addi-
tion, it is proposed that an exposure factor should be considered for
Category 1 (high concern EDs). If the MoE is greater than 1000 then
the Category 1 EDs should undergo normal risk assessment. Only if
the MoE is less than 1000 should a substance be considered as an
endocrine disrupter of regulatory concern to which the hazard
based cut-off criterion should be applied. As a MoE of 100 is con-
sidered health protective for other adverse events then this repre-
sents a highly conservative approach.
2.1. Human relevance
The ﬁrst step, after establishing that there is sufﬁcient weight-
of-evidence for potential endocrine disruption, is to assess whether
the adverse effects observed in in vivo animal studies and the pro-
posed endocrine MoA are relevant to humans. The current default
assumption is to assume human relevance. However, this assump-
tion can be re-evaluated if there are scientiﬁcally valid data to
demonstrate non-relevance to humans. In the case of adverse
endocrine mediated effects observed in experimental animals,
the most well-known example for non-human relevance of animal
data is the susceptibility of the rodent to disruption of thyroid
function due to species-speciﬁc differences in synthesis, binding,
metabolism/clearance and transport of the thyroid hormones. It
has been well documented in the literature that certain hormon-
ally-induced changes of the thyroid in rodents have little relevance
to humans (Ames et al., 1987; Alison et al., 1994).
Other examples of MoA or adverse effects that are not relevant
to humans exist. However, there are few well-documented cases
where endocrine effects in experimental animals are recognised
as not relevant to humans. Furthermore, it is often difﬁcult to
prove a negative, i.e. to prove non-relevance to humans. The IPCS
frameworks for assessing the relevance of cancer and non-cancer
MoA for humans (Boobis et al., 2006, 2008) should be used to
evaluate the available evidence.g ED of concern 
tency
ED of low concern
No No regulatory
concern for ED
t sensitive effect ? No No regulatory 
concern for ED
Standard risk 
assessment
o
Standard risk 
assessment
endocrine disrupters of regulatory concern for human health.
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the substance being evaluated is not of regulatory concern and
should undergo standard risk assessment, rather than be subject
to the hazard based cut-off criterion. If the observed effects and
MoA are deemed to be relevant to humans, or if there are insufﬁ-
cient data to demonstrate non-relevance to humans, then the spec-
iﬁcity of the effects needs to be evaluated (Fig. 1).
2.2. Lead toxic effect and speciﬁcity
The speciﬁcity of an adverse endocrine effect can be assessed by
using the lead toxic effect approach, which considers the dose re-
sponse relationship of all effects observed in the whole toxicity
dossier available for a substance. The adverse effect that occurs
at the lowest dose is considered the lead toxic effect. The lead toxic
effect consequently describes the most sensitive toxicological re-
sponse and drives the risk assessment of a substance. Any risk
management measures based on the lead toxic effect will also be
protective of other toxic effects (including endocrine effects)
occurring at higher dose levels.
Within a study an endocrine mediated endpoint can be affected
at lower, similar or higher doses than those which cause other
types of toxicity. A substance should only be considered of regula-
tory concern, i.e. be subject to the cut-off criterion, when the endo-
crine mediated effect is the lead toxic effect and occurs at doses
lower than those that cause other types of toxicity and a sufﬁcient
MoE cannot be established. In the case where the endocrine med-
iated effect is not the lead effect, i.e. the endocrine effect is ob-
served at higher doses than those causing other toxicity, then the
substance should not be considered an endocrine disrupting chem-
ical of regulatory concern, and should not be subject to the cut-off
criterion. Rather the substance should then proceed with a risk
assessment based on the most sensitive (non-endocrine) lead ef-
fect. A factor of up to 10-fold degree of separation between the lead
effect and an endocrine effect at higher doses may be considered
sufﬁciently conservative for a substance not to be determined as
an endocrine disrupter of regulatory concern. However, each sub-
stance should be evaluated on a case by case basis, taking into ac-
count the dose response and nature and severity of both the
primary lead effect and the endocrine effects.
A hypothetical example describing this principle is depicted in
Fig. 2. The available in vivo data for a hypothetical chemical ‘‘Y’’
provide evidence of adverse effects on endocrine relevant end-
points, i.e. uterine tumours were observed in a two-year rat carcin-
ogenicity study and uterine glandular hyperplasia was noted at the
one-year interim sacriﬁce of the same study. These ﬁndings were
supported by mechanistic data, which provided a plausible endo-
crine mechanism for the adverse effects observed. Progesterone
and testosterone secretion were affected in an in vitro H295R assay,
progesterone and oestradiol were affected in an in vitro steroido-
genesis assay using ovarian follicles, and progesterone and oestra-
diol hormone levels were found to be perturbed in in vivo hormone
studies following single and multiple doses. Based on the ﬁrst half
of the ECETOC guidance there is therefore sufﬁcient evidence for
endocrine disruption. The next step is to assess whether the endo-
crine MoA is relevant to humans in order to determine whether
this substance should be considered of regulatory concern. In this
hypothetical example human relevance has to be assumed, in the
absence of data to the contrary, and the speciﬁcity of the endocrine
effect is considered. The Lowest Observed Adverse Effect Levels
(LOAELs) for the endocrine mediated effects are compared with
the LOAELs for other toxic effects observed. In this example, a
LOAEL of 35 mg/kg/d was determined for the uterine tumours.
However, liver toxicity and liver adenomas were also observed
with a LOAEL of 2 mg/kg/d. The endocrine mediated effect was
therefore not the most sensitive effect, the degree of separationbetween the effects was greater than 10-fold, and the risk assess-
ment should therefore be performed with the NOAEL for the lead
toxic effect (liver toxicity/carcinogenicity). It should be noted that
the uterine tumors would not be ignored; they would result in an
appropriate classiﬁcation according to European Classiﬁcation,
Labelling and Packaging (CLP) criteria.
A fundamental principle of the lead toxic effect approach is that
any risk management measures based on the lead toxic effect will
also be protective of other toxic effects (including endocrine ef-
fects) occurring at higher dose levels. However, there are certain
circumstances in the evaluation of endocrine effects that require
careful consideration. When assessing lead effects, special consid-
eration should be given to the (ir)reversibility of effects. For exam-
ple, if a lead (non-endocrine) effect is found to be reversible,
whereas the endocrine mediated effect observed at a higher dose
is found to be irreversible, then regulation should be based on
the irreversible endocrine mediated effect found at the higher
dose, if more relevant. The irreversibility of effects which are man-
ifest in later life stages, but caused due to exposure at critical time
windows of development should also be given due consideration
when assessing lead toxic effects.
2.3. Potency and exposure
Once it has been established that the endocrine effect is the lead
toxic effect and that the nature of adversity, severity and revers-
ibility of the effect has also been considered (ECETOC, 2002), the
evaluation proceeds to an assessment of potency to discriminate
endocrine disrupters of high (regulatory) concern from those of
lower concern so that more potent chemicals will be regulated dif-
ferently from less potent chemicals.
The potency of a substance is a factor of both the dose level at
which adverse effects are caused and the duration required to
cause the adverse effects. A substance with a lower NOAEL than an-
other for the same endpoint can be considered intrinsically more
potent. Further, a potent substance may cause an adverse effect
after a short exposure duration, whereas a less potent substance
may require a longer exposure duration to elicit the same effect.
In a joint proposal the German Bundesinstitut für Risikobewertung
(BfR) and the UK Chemicals Regulation Directorate (CRD) (Joint DE-
UK position; BfR, 2011) recommend using an approach to potency
that already exists in chemical legislation. In this a combination of
dose level and exposure duration that cause speciﬁc target organ
toxicity is considered. The Joint DE-UK position uses Speciﬁc Target
Organ Toxicity-Repeated Exposure (STOT-RE) criteria to deﬁne po-
tential endocrine disrupters as either endocrine disrupters of high
or low regulatory concern. The STOT-RE criteria are discriminatory
dose thresholds deﬁned in the European CLP Regulations, and are
used to determine whether substances should be identiﬁed by haz-
ard classiﬁcation and be assigned appropriate labelling. The Joint
DE-UK position proposes that the dose thresholds for STOT-RE
should be used to determine whether or not the hazardous prop-
erty of ‘‘endocrine disruption’’ should be considered for regulatory
purposes. The STOT-RE criteria are summarised in Table 1. The CLP
regulations do not provide threshold values for chronic studies, but
the Joint DE-UK position proposed chronic threshold values, which
are half the sub-chronic values (by applying the sub-chronic to
chronic assessment factor of two recommended in the REACH
guidance). When a substance causes an adverse endocrine medi-
ated effect at a dose level at or below the thresholds for the appli-
cation of Category 1 STOT-RE hazard classiﬁcation, the substance is
considered as an endocrine disrupter of high regulatory concern
(i.e. subject to regulatory prohibition or restriction depending on
the relevant legislation). When a substance causes endocrine med-
iated effects at a dose level above the thresholds for Category 1
STOT-RE hazard classiﬁcation, the substance should not be
Sufficient evidence of ED of concern
No adverse health 
effects giving 
concern to ED 
activity
ED activity giving 
concern to ED 
toxicity
Adverse effects 
giving concern for 
endocrine toxicity
Endocrine activity 
giving concern for 
endocrine toxicity
Adverse effects 
giving concern to 
ED toxicity
No Evidence of ED 
Activity
Non-relevance of ED MOA to humans not demonstrated
Endocrine effect is not the most sensitive end-point- 
Perform risk assessment on lowest NOAEL (1 mg/kg/day) 
Specificity 
Assessment
Study Finding(s)
Multi-endpoint studies (apical, in vivo)
2 year rat cancer bioassay Uterine tumours
Supporting studies (non-apical in vivo)
1 year interim sacrifice Uterine glandular hyperplasia
No indications in shorter term studies of uterine effects
Mechanistic data
Study Result
Estrogen receptor density Negative
In vitro steroidogenesis (H295R) Progesterone & testosterone 
secretion affected
In vitro steroidogenesis (ovarian 
follicles)
Progesterone & estradiol 
secretion affected
In vivo hormone studies (single & 
multiple doses)
Progesterone & estradiol plasma 
levels affected
Immature rat uterotrophic assay No effects
Comparison of LOAELs
Study ED LOAEL Lowest LOAEL (Liver effects)
Rat cancer bioassay 35 mg/kg/day 2 mg/kg/day
Fig. 2. Lead toxic effect and speciﬁcity as discriminators in the assessment of endocrine disrupters of regulatory concern for human health for a theoretical example.
Table 1
Summary of dose thresholds for Category 1 and Category 2 classiﬁcation for Speciﬁc
Target Organ Toxicity-Repeated Exposure (STOT-RE).
STOT-RE Cat 1 STOT-RE Cat 2
Sub-acute and other short-term studies (e.g. developmental toxicity studies)
Oral 30 mg/kg bw/day 300 mg/kg bw/day
Dermal 60 mg/kg bw/day 600 mg/kg bw/day
Inhalation (vapour) 0.6 mg/l/6 h/day 3 mg/l/6 h/day
Inhalation (dust/mist/fume) 0.06 mg/l/6 h/day 0.6 mg/l/6 h/day
Sub-chronic and other medium-term studies (e.g. 2-generation reproduction
studies)
Oral 10 mg/kg bw/day 100 mg/kg bw/day
Dermal 20 mg/kg bw/day 200 mg/kg bw/day
Inhalation (vapour) 0.2 mg/l/6 h/day 1 mg/l/6 h/day
Inhalation (dust/mist/fume) 0.02 mg/l/6 h/day 0.2 mg/l/6 h/day
Chronic studiesa
Oral 5 mg/kg bw/day 50 mg/kg bw/day
Dermal 10 mg/kg bw/day 100 mg/kg bw/day
Inhalation (vapour) 0.1 mg/l/6 h/day 0.5 mg/l/6 h/day
Inhalation (dust/mist/fume) 0.01 mg/l/6 h/day 0.1 mg/l/6 h/day
a There are no guidance values in the CLP Regulations for chronic studies, but the
Joint DE-UK position proposes that the guidance values for chronic studies should
be half the subchronic study values (by applying the subchronic to chronic
extrapolation assessment factor of two recommended in the REACH guidance on
information requirements and chemical safety assessment, chapter R8).
R. Bars et al. / Regulatory Toxicology and Pharmacology 64 (2012) 143–154 147considered as an endocrine disrupter of high regulatory concern
(i.e. not subject to the severe regulatory consequences). Rather,
these substances should be regulated through standard risk assess-
ment and risk management methodologies.
The method proposed in the Joint DE-UK position has merit in
being practical and the ECETOC task force considers it to be a rea-
sonable approach. It is a pragmatic solution that in the absence of
existing science-based potency factors is at least well founded in
existing EU regulation. Therefore, a potency assessment based on
STOT-RE criteria, such as that proposed by the Joint DE-UK posi-
tion, could be used within the ECETOC framework to discriminateendocrine disrupters of high regulatory concern from those of low
regulatory concern. Endocrine disrupters causing effects at a dose
level at or below the dose thresholds for the application of Cate-
gory 1 STOT-RE hazard classiﬁcation would be considered of high
concern subject to regulatory action. Those causing effects above
the dose threshold for Category 1 STOT-RE hazard classiﬁcation
would be considered of low concern, and would not be subject to
regulatory action, but would proceed to standard risk assessment.
If a substance is considered to be of high concern, the proposed
ECETOC approach proceeds to an assessment of exposure. A sub-
stance may be a highly potent endocrine disrupter, but if the expo-
sure concentrations are so low that humans are not exposed to an
effective dose, then the substance should not be considered of high
regulatory concern. A very conservative and health protective MoE
of 1000 is proposed for the exposure assessment. The NOAEL for
endocrine disrupting effects is compared with the estimated expo-
sure dose for humans, and if this results in a MoE greater than
1000, then the substance should not be considered of high regula-
tory concern and proceeds to risk assessment. However, if the MoE
is less than 1000 then the substance should be determined as an
endocrine disrupter of high regulatory concern, to which the cut-
off criterion may be applied.
The use of potency and exposure as a discriminating factor in
the assessment of endocrine disrupting properties can be illus-
trated with the example of the non-steroidal oestrogenic myco-
toxin, zearalenone (Fig. 3). The available in vivo data and in vitro
data provide sufﬁcient evidence of endocrine disruption. In sum-
mary, pituitary adenomas were observed in chronic toxicity
studies in the mouse (NTP, 1982), whilst pituitary, thyroid and
adrenal weights were affected in a rat multi-generation study
(Becci et al., 1982). Testicular and seminal vesicle atrophy, as well
as hyperplasia of the prostate, mammary gland ducts and endome-
trial tissue were found in a 90-day study with rats (NTP, 1982). In
pigs, increased inter-oestrus interval, increased plasma progester-
one levels, and prolonged maintenance of corpora luteawere found
following a dosing period of 15 days (Edwards et al., 1987).
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(Kuiper et al., 1998), affects progesterone and testosterone secre-
tion in in vitro steroidogenesis assays (Frizzell et al., 2011; Yang
et al., 2007), and induces increased uterine weight in the utero-
trophic assay (Christensen et al., 1965; Ueno et al., 1974). The
MoA is considered relevant for humans, and the adverse endocrine
effects were the lead toxic effects, occurring at doses lower than
other forms of toxicity. The most sensitive NOAEL for adverse
effects relevant for the assessment of endocrine disruption was
40 lg/kg bw/day in the 15-day pig study and the corresponding
LOAEL was 200 lg/kg bw/dAY. The LOAEL of 200 lg/kg bw/day
falls below the oral dose threshold (short-term studies: 30 mg/
kg bw/day) for application of Category 1 STOT-RE hazard classiﬁca-
tion and the substance is considered as an endocrine disrupter of
high regulatory concern. The next step in the evaluation is to con-
sider the MoE. The estimate for average daily intakes of zearale-
none in European diets corresponds to approximately 0.03 lg/
kg bw/day (EC, 2000), resulting in an MoE greater than 1000
(NOAEL of 40 lg/kg bw/d divided by the estimated exposure dose
of 0.03 lg/kg bw/day = 1333). It is proposed that substances with
MoEs greater than 1000 undergo standard risk assessment. The
EC Scientiﬁc Committee on Food has used exactly this approach
to set a Tolerable Daily Intake (TDI) of 0.2 lg/kg bw/day for zearal-
enone, based on the NOAEL of 40 lg/kg bw/day and an assessment
factor of 200 (EC, 2000).
3. Reﬁnements to the ECETOC proposal to identify EDCs of
regulatory concern in ecotoxicology
The assessment of endocrine disrupting effects in wildlife spe-
cies is undertaken separately for aquatic (ﬁsh and amphibians)
and terrestrial vertebrates (birds and mammals). Assessment for
birds and mammals is particularly relevant to the regulation ofSufficient evidence of 
ED MoA relevant 
Lead effect of endocrin
No adverse health 
effects giving 
concern to ED 
activity
ED activity giving 
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Adverse effects 
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Fig. 3. Potency as a discriminator in the assessment of endocrine disruptersplant protection and biocidal products, with a tiered requirement
for testing under REACH depending on tonnage bands, whilst the
assessment for ﬁsh and amphibians is also relevant under a range
of other EU regulatory directives (e.g. REACH, water framework
directive). The ﬁrst half of the ECETOC guidance outlines the test-
ing and evidence required to determine whether a substance has
endocrine disrupting properties in wildlife species (the reader is
referred to Bars et al. 2011 for details). The guidance considers
the results from targeted in vitro screens, targeted mechanistic
in vivo screening assays, and apical (deﬁnitive) and supporting
in vivo assays to establish evidence of an adverse population rel-
evant effect with an understanding of the MoA underlying these
effects. A holistic evaluation of all the data will be required to as-
sess whether a substance should be regarded as an endocrine dis-
rupter according to the IPCS deﬁnition. Therefore, a consistent
weight-of-evidence evaluation is required to contend with the
varying levels of signiﬁcance and relevance of the various test
types. This need has been re-afﬁrmed in the publication of gen-
eral weight-of-evidence considerations by the US EPA for evalua-
tion of their Endocrine Disrupter Screening Program results (US
EPA, 2011), as well as in the draft OECD Guidance Document on
standardised test guidelines for evaluating chemicals for endo-
crine disruption (OECD, 2011). A similar framework to the
WHO/IPCS MoA framework for the assessment of cancer and
non-cancer endpoints, which is recommended for the human
health assessments, is currently not available for ecotoxicological
assessments. However, various guidance documents exist for
weight-of-evidence evaluations speciﬁc to endocrine disruption
(e.g. LRI-EMSG, 2000; Brown et al., 2001; Borgert et al. 2011).
These existing methodologies should be evaluated and useful ele-
ments combined to assist with developing current regulatory
requirements. Two common components of the existing weight
of evidence methodologies are: (a) assessment of data quality,ED of concern? YES
to humans? YES
e nature? YES
Endocrine activity 
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of regulatory concern for human health – illustrated with zearalenone.
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categories need to be modiﬁed and expanded to be more relevant
for ecotoxicological assessments, and (b) a form of weighting
based on the relevance of individual studies for the assessment
of endocrine disruption.
In the evaluation of the available evidence for environmental
assessments, speciﬁc consideration needs to be given to the pop-
ulation relevance of any adverse effect (Fig. 4). This is discussed
in further detail in Section 3.1. The identiﬁcation of endocrine
disrupting properties is then followed by an assessment of endo-
crine speciﬁcity, to determine whether the adverse effects
observed occur at dose/concentration levels equal to or lower
than general toxicity. The assessment of speciﬁcity is conducted
at two levels. The ﬁrst level is to consider the speciﬁcity within a
study or taxon. This forms part of the evaluation to determine
whether a substance meets the agreed deﬁnition of an endocrine
disrupter, i.e. causing an adverse effect, secondary (consequent)
to changes in endocrine function (Fig. 4, Section 3.2). Once it
has been identiﬁed that there is sufﬁcient evidence as per the
IPCS deﬁnition, the evaluation proceeds to the second level,
where speciﬁcity is considered in relation to endpoints of other
taxonomic groups in the same environmental compartment,
which may drive the overall risk assessment (Fig. 4, Section 3.2).
If the adverse effects are considered not speciﬁc at this stage, the
substance proceeds to risk assessment based on the non-endo-
crine endpoint. However, if the adverse effects are speciﬁc, then
the potency of the substance should be considered (Fig. 4, Sec-
tion 3.3). The substance proceeds with a risk assessment based
on the endocrine endpoint with an assessment factor based on
potency, unless exposure is negligible and no risk assessment
is required (Fig. 4, Section 3.4). The environmental assessment
deviates at this stage from the assessment for human health,
i.e. all substances proceed to a risk assessment and there is no
initial hazard-based screening or exclusion. This is because there
are no readily available threshold values for ecotoxicology in
existing legislation (such as the CLP regulations) that are suit-
able. The CLP threshold values for classiﬁcation of long-term
aquatic hazards can be as high as 100 mg/L or as low as
0.01 mg/L.Weight of evidenc
available data sho
• adverse;
• population relev
• explained by en
• specific (within 
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specific (most se
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Fig. 4. Summary overview of the reﬁned ECETOC proposal to identify3.1. Adversity and population relevance
There are speciﬁc differences between the ﬁelds of human
health and environmental risk assessment that require a different
approach to be taken for the assessment of endocrine disrupting
effects in wildlife species. In contrast to the human health assess-
ment, the protection goal of environmental assessments is the pro-
tection of populations rather than individuals (Suter et al., 1993;
EFSA, 2010a). This difference in protection goals between human
and environmental risk assessments is particularly important to
the determination of endocrine disrupting properties of chemicals.
It requires speciﬁc consideration of adversity in relation to the pop-
ulation relevance of endpoints measured in ecotoxicological
studies.
An adverse effect has been deﬁned as follows: ‘‘A change in the
morphology, physiology, growth, development, reproduction, or
life span of an organism, system, or (sub)population that results
in an impairment of functional capacity, an impairment of the
capacity to compensate for additional stress, or an increase in sus-
ceptibility to other inﬂuences’’ (IPCS, 2004). This IPCS deﬁnition of
an adverse effect includes consideration of a population level ef-
fect. Since the protection level is set at the population level for
environmental assessments, for an effect to be considered adverse
it should have the potential to impact at the population level. In or-
der to determine that a substance has endocrine disrupting proper-
ties, population relevant endpoints need to be associated with
speciﬁc endocrine mechanisms of action (Bars et al., 2011a). How-
ever, many non-speciﬁc endpoints (e.g. growth) may also be of
population signiﬁcance. Therefore, for the assessment of endocrine
disruption, the endpoints of interest are adverse population level
effects that are a consequence of disturbance of the endocrine sys-
tem in deﬁnitive (apical) tests.
Population relevant effects are those that affect population
growth or dynamics. For example: age at ﬁrst reproduction, size
of a reproductive event, frequency of reproductive events, duration
of reproductive period, viability of young and sex ratio. Clearly,
some of these effects are population relevant and also diagnostic
of endocrine modulation (e.g. sex ratio in ﬁsh in the absence of
gender-dependent mortality). However, some effects are knowne evaluation of all 
w that effects are:
ant;
docrine MoA and
the species/taxon)
No
s per IPCS definition of ED
mediated effect 
nsitive) across 
a? No
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endocrine disrupters of regulatory concern for wildlife species.
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nostic of, endocrine modulation (e.g. fecundity, which can be af-
fected by general toxicity). In such circumstances supporting
information within a test (co-occurring diagnostic endpoints, e.g.
vitellogenin in the case of ﬁsh2) or information from other in vivo
testing tiers (diagnostic endpoints from screening assays at similar
doses/concentrations) will be required to link the population rele-
vant effect to an endocrine mechanism. This principle could be ap-
plied to all taxonomic groups being assessed (ﬁsh, amphibians,
birds and mammals) with the exception of invertebrates for which
there are no widely accepted mechanistic endpoints.
In practical terms, it is useful to consider the population rele-
vance of the different endpoints. As the science and our level of
understanding evolve, further linkages to population impact may
become established. Currently, there is a general acceptance that
mechanistic endpoints in isolation do not necessarily imply ad-
verse effects and so are employed as ‘‘signposts’’ (Hutchinson
et al., 2006) in the testing and interpretation logic rather than
directly in risk assessment (Knacker et al., 2010). Thus a consider-
ation of endpoints is necessary and this should constantly be re-
evaluated to allow for future improvements in our understanding.
For example, using approaches such as those described by the
Adverse Outcome Pathway concept (Ankley et al., 2010) may help
establish robust linkages between mechanistic endpoints and
adverse effects.
Regulatory tests that measure endocrine-mediated and non-
endocrine-mediated population relevant effects are essentially
those at level 5 (potentially also level 4 on an endpoint by endpoint
basis) of the OECD’s Conceptual Framework for the Testing and
Assessment of Endocrine Disrupting Chemicals. For ﬁsh and
amphibians, these are the ﬁsh sexual development test (OECD TG
234), ﬁsh life-cycle tests (e.g. OPPTS 850–1500 or medaka multi-
generation test currently under development) and the amphibian
growth and development test (currently under development). For
birds, they are the chronic reproduction test (OECD TG 206) and
the avian two generation test (currently under development). For
wild mammals, they are the two generation rodent test (OECD
TG 416), the extended one generation reproduction study (OECD
TG 443) and other tests that may also be useful in the determina-
tion of apical population level effects (OECD TG 414, TG 408 and TG
407). The endocrine diagnostic endpoints may come from these
studies or from additional in vivo screening assays (levels 3 and 4
of the conceptual framework). As described previously (ECETOC,
2009a; Bars et al., 2011a) for mechanistic endpoints to be consid-
ered reliable they should be observed in the absence of systemic
toxicity.
Clearly there will be a hierarchy and weight-of-evidence ele-
ment in interpreting ﬁndings for particular substances. Certain
clusters of endpoints will be more signiﬁcant than a single end-
point in isolation, unless the magnitude of change in that ﬁnding
is very compelling. Therefore, expert judgement will be required
to make the link between endocrine-mediated endpoints and pop-
ulation relevant effects. This will inevitably need to incorporate
thinking around what constitutes a biologically meaningful effect
as opposed to merely a statistically signiﬁcant effect. For example,
very low changes in response variables (e.g. 3%) can be statistically
signiﬁcant (depending on the number of animals/replicates, homo-
geneity of starting populations, measurability etc.) but may be bio-
logically irrelevant for population maintenance or even individual
performance. In studies with many endpoints, e.g. the multi-gener-
ation tests, the probability of detecting an ‘‘effect’’ as a type I error2 This should be considered preliminary since the amphibian metamorphosis assay
is a screening test and is not optimised to assess apical effects for use in risk
assessment (e.g. large spacing factor between only three test concentrations and
apical measures on relatively few individuals).increases. Therefore, interrogation of the data for biological rele-
vance becomes increasingly important with the number of end-
points measured. Thus, for environmental risk assessments the
concept of NOAEL may be a useful tool to help distinguish the mag-
nitude of effect, though it should be recognised that this does not
always address population relevance within a study. Another
equally important consideration is the question of what consti-
tutes co-occurrence of mechanistic symptoms and population rel-
evant effects, i.e. can they be found at the same concentration or
dose suggesting a causal relationship? Further research is required
to address these issues.
3.2. Speciﬁcity
As described in Section 2.2 for the human health assessment,
the speciﬁcity of an endocrine effect can be assessed by using the
lead toxic effect approach. The lead toxic effect describes the most
sensitive ecotoxicological response and drives the risk assessment
of a substance. Any risk management measures based on the lead
toxic effect will also be protective of other toxic effects (including
endocrine effects) occurring at higher dose levels. For environmen-
tal assessments the lead toxic effect can be considered within a
study/species (or taxon) or amongst different studies/taxa within
an environmental compartment.
3.2.1. Speciﬁcity within a study
Within a study an endocrine mediated endpoint can be affected
at a lower, the same or higher dose/concentration than that caus-
ing general toxicity. This should be considered in the ﬁrst part of
the original ECETOC assessment (ECETOC, 2009a), when linking
mechanistic and apical in vivo studies to decide whether a sub-
stance is a potential endocrine disrupter of regulatory concern or
not (Fig. 4).
A substance should only be considered of regulatory concern
when the endocrine mediated effect is the lead effect and occurs
at concentrations lower than those that cause other signiﬁcant tox-
icity. In the case where the endocrine mediated effect is not the
lead effect, i.e. the endocrine effect is observed at a higher concen-
tration than that causing other toxicity, then the substance should
be considered of low concern. The substance should then proceed
with a risk assessment based on the most sensitive (non-endo-
crine) endpoint.
A hypothetical example of a potential aromatase inhibiting
chemical tested in a ﬁsh full life-cycle study can be used to demon-
strate the principle. For example, if the chemical induces a sex ratio
shift as the most sensitive or lead effect, the substance would be
considered of regulatory concern and proceed to the next step in
the assessment. However, if the lead effects are early lifestage mor-
tality and decreased growth, with a decrease in reproduction (cor-
related with a decrease in vitellogenin) observed at higher
concentrations, then the substance should proceed to a risk assess-
ment based on the non-endocrine lead effect. This rationale would
also apply if the endocrine mediated endpoints occurred at the
same concentration as the other systemic effects.
It is possible to quantify this effect by dividing the endocrine-
mediated NOEC by the non-endocrine NOEC from chronic apical
tests with ﬁsh and amphibians. The resulting ratio can be used to
indicate if the endocrine endpoints are speciﬁc and whether they
drive the risk assessment. If the ratio is less than 1, the endocrine
mediated effects would be considered speciﬁc, as they occur at a
concentration lower than that causing other general toxicity, and
the substance would proceed to the next step in the evaluation.
If the resulting ratio is greater than 1, the endocrine mediated ef-
fects would not be considered speciﬁc. The substance would pro-
ceed to a risk assessment, which would have a built-in margin of
safety for the endocrine effects occurring at higher concentrations
R. Bars et al. / Regulatory Toxicology and Pharmacology 64 (2012) 143–154 151than the lead toxic effect. If the ratio equals or is close to one then
the substance is causing endocrine effects and general systemic
toxicity at the same or similar concentrations. In this case the
endocrine effects would not be considered speciﬁc. The same ap-
proach to quantify speciﬁcity is followed for birds and mammals
using the endocrine-mediated NO(A)EL and the lowest non-endo-
crine-mediated NO(A)EL from chronic tests (but only when dosed
via the diet; gavage studies are not applicable (EFSA, 2010b)).
The acute-to-chronic ratio (ACR) may also be used as an indica-
tor to determine whether the endocrine mediated effects are spe-
ciﬁc and warrant further evaluation within the framework or
whether they would be covered through a standard risk assess-
ment. The ACR is deﬁned as the LC50 or LD50 from a short-term
acute study, divided by the NO(A)EC or NO(A)EL from a long-term
chronic study. A small ACR is associated with substances with a
general MoA (e.g. narcotics) because the MoA remains the same
in acute and chronic exposures. This means that the effects mea-
sured in a chronic study are a smaller magnitude of the same type
of response (e.g. NOEC for survival versus LC50). If another MoA
becomes active, then the ACR is generally larger. For example, ACRs
for 17b-oestradiol, ethinyloestradiol and methyltestosterone in
ﬁsh are reported as 390,000; 150,000 and >1,000,000, respectively
(Hutchinson et al., 2003). In contrast, the average ACR for eleven
non-polar narcotics was reported as 2.58 (Roex et al., 2000) and
an extensive analysis of a large database of substances demon-
strated that the ACR was commonly in the range of 4–50, with a
slightly broader range of 1–70 covering around 90% of cases (ECE-
TOC, 2003). The ﬁsh ACR for endocrine effects is calculated by tak-
ing the 96-h LC50 and dividing it by the lowest NOEC for an
adverse endocrine mediated effect from the apical study (i.e. ﬁsh
lifecyle study or ﬁsh sexual development test). For amphibians
there is currently no standardised acute test to derive an LC50
from. Further, the apical growth and development test is still under
development by the OECD. Only the amphibian screening assay
(OECD 231) is available from which a preliminary3 NOEC can be de-
rived. This preliminary amphibian NOEC could be compared with the
ﬁsh 96-h LC50 (which is acceptable since acute ﬁsh and amphibian
toxicity data are highly correlated (Aldrich, 2009)). If the resulting
ACR is low, then endocrine speciﬁcity of the substance in question
is unlikely. Knacker et al. (2010) proposed an ACR of 20 for ﬁsh as
an indicator of speciﬁc effects. Furthermore, if the ACR is 610 then
the effects would already be covered by the assessment factor ap-
plied in a standard risk assessment.
The ACR principle described above is, in principle, also applica-
ble to birds and mammals. However, in contrast to the aquatic
ﬁeld, the ACR concept is hardly used in terrestrial vertebrate
assessments. The ACR for endocrine effects is calculated by divid-
ing the LD50 from the acute avian or mammalian study by the low-
est NO(A)EL for the adverse endocrine-mediated effects obtained
in the available reproduction study (and in future potentially the
bird two-generation study, which is currently under development).
Of course both endpoints need to be expressed in corresponding
units, i.e. mg/kg bw/day. For mammals, the rat and for birds, mal-
lard or quail will be the likely species available for comparisons. It
should also be noted that only chronic studies in which animals are
exposed via the diet are applicable; gavage dosing is considered
inappropriate for the derivation of population-relevant adverse ef-
fects (EFSA, 2010b). There is no standard factor (such as the value
of 10 for aquatic organisms) against which to compare the avian or
mammal ACR, so that a judgement on the speciﬁcity of the effects
is not trivial. Therefore, it would be useful to develop an avian and3 This should be considered preliminary since the amphibian metamorphosis assay
is a screening test and is not optimised to assess apical effects for use in risk
assessment (e.g. large spacing factor between only three test concentrations and
apical measures on relatively few individuals).mammalian database from which reference values can be derived.
In the bird and mammal risk assessment for plant protection prod-
ucts, there is only a factor of two between acute and chronic Tox-
icity Exposure Ratio (TER) values, but in contrast to the aquatic risk
assessment exposure values are not the same.
3.2.2. Speciﬁcity across taxa
Once a population relevant endocrine effect has been conﬁrmed
as the lead effect within a taxon, then sufﬁcient evidence of endo-
crine disrupting properties has been demonstrated according to
the IPCS deﬁnition. The next step in the environmental evaluation
is to consider the speciﬁcity and lead effect across taxa. Although
endocrine effects may be observed as the most sensitive lead effect
within one study or organism (generally the taxonomic group), this
effect may be accounted for in a risk assessment by more sensitive
non-endocrine endpoints observed in other taxonomic groups.
Taking a holistic overview of the compartment, the (aquatic or ter-
restrial) risk assessment allows for a margin of safety that may suf-
ﬁciently cover endocrine speciﬁc effects observed in one of the
taxonomic groups considered. Any risk management measures
based on the lead toxic effect in one taxon will also be protective
of other toxic effects (including endocrine effects) occurring at
higher concentration/dose levels in another taxon. For example,
one can envisage a scenario where the assessment is driven by
one taxonomic group due to a herbicidal MoA of a chemical
(Fig. 5). This herbicide may cause oestrogenic effects in ﬁsh at rel-
atively high concentrations. However, in the example presented,
the most sensitive lead effect is the toxicity to macrophytes at a
concentration of the herbicide 30-fold lower than that causing
endocrine mediated effects in ﬁsh. In this case the herbicide should
not be considered of regulatory concern and should proceed to a
risk assessment based on the lower endpoint on primary producers
(which of course will have an assessment factor of 10 applied). The
endocrine effect on ﬁsh would not be considered relevant under
conditions of safe use described by the risk assessment and the
safety margin provided.
3.3. Potency
Once it has been established that the endocrine effect of a sub-
stance is the lead effect, both within and across taxa, the evaluation
proceeds to an assessment of potency to discriminate endocrine
disrupters of regulatory concern from those of low concern. All
substances proceed with a risk assessment using assessment fac-
tors based on potency (Fig. 4). The size of potency based assess-
ment factors to be used is an area for further development.
Potency in the context of endocrine disruption is a measure to esti-
mate at which concentration or dose a chemical can induce an
endocrine mediated adverse (population relevant) effect. Hence,
this aspect is strongly linked to speciﬁcity but aims to be more
quantitative. Therefore, the endocrine-mediated NOEC/NO(A)EL
needs to be compared with other endpoints. This can be done by
calculating various measures, such as assessing the magnitude of
the ACR, comparing the potency of the substance to a reference
compound (e.g. the natural ligand of interest, such as 17b-oestra-
diol for oestrogen receptor mediated effects), consideration of the
duration of exposure that is required for an adverse effect to be in-
duced, as well as the number of species in which the adverse effect
is demonstrated. These measures are considered in more detail
below.
3.3.1. Acute-to-chronic (endocrine) ratio
The use of ACRs has already been discussed in relation to the
assessment of speciﬁcity in Section 3.2 above. In addition to pro-
viding information on the likely speciﬁcity of a substance (indi-
cated by a large ACR), the magnitude of the ACR will also provide
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Fig. 5. Endpoints for a hypothetical substance (herbicide). In this case, a factor of 30
exists between the endocrine-mediated ﬁsh NOEC and the macrophyte endpoint
that drives the risk assessment. The endocrine-mediated endpoint in ﬁsh is non-
speciﬁc and the substance is not an endocrine disruptor of regulatory concern.
4 http://register.consilium.europa.eu/pdf/en/11/st05/st05032-re02.en11.pdf.
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for a weak endocrine disrupter may be greater than the general
ACR range for non-speciﬁc acting chemicals (ACR range of 1–70),
but it may not be of the magnitude of the endogenous hormones
(ACR range of 150,000 to >1,000,000; Hutchinson et al., 2003).
3.3.2. Comparison with a reference compound
A comparison of the endocrine mediated NOEC/NO(A)EL of a
chemical with a known endocrine mechanism of action can be
made with that of a standard reference compound, e.g. 17b-oestra-
diol, testosterone or fadrozole, assuming that these compounds
have a potency of one. Then the potency (e.g. oestrogenic, andro-
genic or aromatase inhibiting) of a compound can be calculated
as the ratio of NOECs/NO(A)ELs. To be able to do this agreed end-
points need to be available for all relevant test systems and refer-
ence compounds covering the necessary mechanisms of action.
Data generated to validate the (OECD) tests or assays, from which
the NOECs/NO(A)ELs are derived from, may be used for this pur-
pose. Finally, categories could be agreed to differentiate potent
from non-potent endocrine active chemicals.
3.3.3. Other potency considerations – duration
When similar endpoints can be derived from various studies
(e.g. ﬁsh reproduction in the ﬁsh short term reproduction assay
and ﬁsh life-cycle test) a comparison can be made if effects occur
already in the short-term study or only after longer exposure in
the life-cycle study at comparable dose levels. It should be borne
in mind that due to the differences in test designs there may be
distinct differences in statistical power and resolution of effect lev-
els (spacing factors between treatments) of the tests, hamperingcomparisons. Further, in long-term tests the same endpoint is often
measured several times and the earlier measurements can be com-
pared with the later measurements (alternatively on a higher level,
effects in the ﬁrst generation can be compared with those in the
second generation). As exposure of wildlife species under natural
conditions is often rather periodic than continuous, effects that
are invoked only after long-term continuous exposure are less
likely to occur and hence are of lower concern (i.e. the compound
is of lower potency). Further, the occurrence of long-term effects
after realistic exposures can be substantiated in specially designed
pulse-exposure studies. For example, Knudsen et al. (2011) inves-
tigated the uptake and biomarker responses (vitellogenin induc-
tion) in ﬁsh following pulsed exposure to 17b-oestradiol. Such
studies may assist in differentiating chemicals into more and less
potent ones. A differentiation should be made in such an evalua-
tion between adverse population-relevant endpoints and diagnos-
tic (bio)markers.
3.3.4. Other potency considerations – number of species affected
When endocrine-mediated effects occur in multiple species, the
potency is considered higher than when the effect occurs in only
one species. Effects should be related to a single endocrine MoA.
In the toxicology database various mammal species may be avail-
able (e.g. rat, mouse, rabbit, dog) while in ecotoxicology ﬁsh, bird
and possibly amphibian studies are available. The differences in
exposure route – birds and mammals with oral exposure (includ-
ing potential metabolism) and ﬁsh and amphibians with whole
body (water) exposure, thereby largely bypassing metabolism,
should be considered when comparing species.
3.4. Negligible exposure
According to the new Eurpean Union regulation for plant pro-
tection products (1107/2009) (EC, 2009a) a substance, which is
considered to have endocrine disrupting properties, can be ap-
proved if exposure of wildlife species to that substance under real-
istic proposed conditions of use is negligible. A similar derogation
is found in the proposed revision of the regulation for biocidal
products (2009/0076 (COD)4 (EC, 2009b). In the proposed biocide
regulation exposure is considered negligible for both humans and
the environment ‘‘in particular where the product is used in closed
systems or strictly controlled conditions’’. Whilst negligible expo-
sure is also deﬁned for human health assessments in the new plant
protections products regulation, there are currently no speciﬁed cri-
teria for ‘‘negligible exposure of wildlife species’’ to plant protection
products. Based on the wording in the regulation it is evident that
negligible exposure must fall somewhere between ‘‘no exposure’’
(i.e. nominal concentrations of 0, or less than the limit of detec-
tion/limit of quantiﬁcation) and a concentration representing an
acceptable or low risk. Passing the usual risk assessment trigger is
not sufﬁcient. A differentiation is made between acceptable expo-
sure that leads to the determination of acceptable risk in the assess-
ment and negligible exposure.
Consideration of negligible exposure should focus on exposure
of the organism group for which endocrine disruption has been
demonstrated in earlier stages of the assessment. Exposure of
other organism groups (e.g. in a different environmental compart-
ment) at higher levels is not relevant in this context. This links with
the consideration of speciﬁcity amongst taxa discussed in
Section 3.2.
Negligible exposure can be deﬁned by consideration of the
application type or through the use of assessment factors during
the risk assessment. Qualitative information on application meth-
ods can be used to deﬁne negligible exposure, since application
R. Bars et al. / Regulatory Toxicology and Pharmacology 64 (2012) 143–154 153scenarios exist in which exposure would be expected to be negligi-
ble, e.g. application methods that avoid exposure of non-target
wildlife species. The use of baits and feeders are examples that
avoid such exposures.
Negligible exposure could also be assessed within the risk
assessment for a substance. Thus, for substances with potential
endocrine disrupting properties the margin of safety should be
considered. For example, if there is a large margin between the
NO(A)EC/NO(A)EL for endocrine effects and the exposure value
(i.e. a high toxicity exposure ratio), then this may be considered
as negligible risk of potential effects. Alternatively, it is possible
to use additional assessment factors for endocrine endpoints to de-
rive ‘‘negligible exposure’’ from ‘‘acceptable exposure/low risk’’. It
is evident that clear criteria for negligible exposure of non-target
organisms to be used under the plant protection products legisla-
tion needs to be developed and agreed.4. Summary and conclusions
The guidance proposed by ECETOC (Bars et al., 2011a) provides
a structured, science based framework to evaluate results from a
variety of apical, mechanistic and screening toxicity studies. It
integrates knowledge of adverse effects and MoA from these stud-
ies to reach a conclusion regarding the endocrine disrupting prop-
erties of substances, in accordance with the IPCS and other related
deﬁnitions. This paper proposes reﬁnements mainly to the second
part of the original ECETOC guidance, in order to discriminate be-
tween chemicals of low concern from those of higher concern
(for regulatory purposes). The concepts of lead toxic effect and po-
tency, which also take into account the nature, severity and revers-
ibility of the adverse effects, are proposed in order to bring the
hazard-based cut-off criterion for endocrine disrupters more in line
with scientiﬁc principles, so that potent endocrine disrupters will
be regulated more stringently than the less potent. The revised
guidance presents a consistent approach, and shares some ele-
ments with guidance proposed jointly by the German BfR and UK
CRD, and the German Umweltbundesamt.
For human health assessments there are empirical well-deﬁned
threshold values in the CLP regulations that can be used to discrim-
inate between those chemicals of high regulatory concern subject
to strict regulatory action from those of lower regulatory concern.
However, it should be noted that the additional criteria such as
potency are not proposed to deﬁne whether a substance is an
endocrine disrupter or not. Substances of lower regulatory concern
would still be regarded as endocrine disrupters, but rather than
being subject to hazard-based prohibition such substances would
undergo risk assessment. For environmental assessments there
are no similar thresholds in the CLP regulations that are suitable
for potency discrimination of endocrine disrupting properties.
Therefore, for environmental assessments all substances proceed
to risk assessment with assessment factors based on potency.
For human health assessments the debate should now move
from developing the concept to running many case studies through
the revised framework. For ecotoxicological assessments further
development is needed for the criteria proposed to allow them to
be fully operational in a regulatory context. ECETOC hopes that
the criteria proposed in this paper will contribute to the ongoing
development of regulatory guidance under the relevant
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